Notably, high MYBL1 levels were associated with poor prognosis in HCC patients, and MYBL1 was identified as a promotor of tumor angiogenesis and sorafenib resistance in HCC cells stably expressing MYBL1 (HepG2-MYBL1 cells) by activation of angiopoietin 2 (ANGPT2). This evidence concerns the gene MYBL1 and neoplasm.